

CORRECTED VERSION

(19) World Intellectual Property
Organization
International Bureau



WIPO | PCT



(10) International Publication Number
WO 2018/067331 A9

(43) International Publication Date
12 April 2018 (12.04.2018)

(51) International Patent Classification:

A61K 39/395 (2006.01) *C07K 16/44* (2006.01)
C07K 16/28 (2006.01) *C07K 16/46* (2006.01)
C07K 16/30 (2006.01)

(21) International Application Number:

PCT/US2017/053113

(22) International Filing Date:

22 September 2017 (22.09.2017)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

62/399,249 23 September 2016 (23.09.2016) US
62/558,711 14 September 2017 (14.09.2017) US

(71) Applicant: **REGENERON PHARMACEUTICALS, INC.** [US/US]; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US).

(72) Inventors: **HABER, Laurie**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **SMITH, Eric**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **KELLY, Marcus**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **KIRSHNER, Jessica R.**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **COET-ZEE, Sandra**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **CRAWFORD, Alison**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **NITTOLI, Thomas**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **LIU, Yashu**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US).

(74) Agent: **TERMES, Lance A.**; Schwabe, Williamson & Wyatt PC, 1211 SW 5th Ave., Suite 1900, Portland, Oregon 97204 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,

HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*
— *with amended claims (Art. 19(1))*
— *with sequence listing part of description (Rule 5.2(a))*

(48) Date of publication of this corrected version:

07 June 2018 (07.06.2018)

(15) Information about Correction:

see Notice of 07 June 2018 (07.06.2018)

(54) Title: BI SPECIFIC ANTI-MUC16-CD3 ANTIBODIES AND ANTI-MUC16 DRUG CONJUGATES

(57) Abstract: The present disclosure provides anti mucin 16 antibodies : bispecific antibodies (bsAbs) that bind to both MUC16 and CD3 and activate T cells via the CD3 complex in the presence of MUC16-expressing tumors. human IgG antibodies that bind to human and MUC16 (monospecific antibodies).anti-MUC16 antibody drug conjugates which inhibit tumor growth in vivo The antibodies are useful for the treatment of various cancers, including ovarian cancer.

WO 2018/067331 A9